These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33145712)

  • 1. The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer.
    Wallace K; Adamski K; Pai A; Rose D; Chawla A
    Pharmacoeconomics; 2021 Feb; 39(2):231-241. PubMed ID: 33145712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
    Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
    J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.
    Liu J; Hawkes C; Walder L; Spalding C; Travers K; Maiese EM; Hurteau J
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1377-1387. PubMed ID: 34595950
    [No Abstract]   [Full Text] [Related]  

  • 4. Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
    Proudman D; Miller A; Nellesen D; Gomes A; Mankoski R; Norregaard C; Sullivan E
    JAMA Netw Open; 2020 Nov; 3(11):e2025866. PubMed ID: 33201235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
    Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
    J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 7. Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective.
    Paly VF; Li S; Khanduri P; Asfaw AA; Zou D; Hernandez L
    J Med Econ; 2024; 27(1):1076-1085. PubMed ID: 39102473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans.
    Li Y; Heer AK; Sloane HS; Edelstein DL; Tie J; Gibbs P; Barzi A
    JAMA Health Forum; 2024 May; 5(5):e241270. PubMed ID: 38819797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.
    Danese MD; Reyes C; Northridge K; Lubeck D; Lin CY; O'Connor P
    Clin Ther; 2008 Apr; 30(4):775-84. PubMed ID: 18498925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives.
    Yang J; Liu R; Ektare V; Stephens J; Shelbaya A
    Appl Health Econ Health Policy; 2021 Jul; 19(4):605-618. PubMed ID: 33506318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring
    Stargardter M; McBride A; Tosh J; Sachdev R; Yang M; Ambavane A; Mittal M; Vioix H; Liu FX
    J Med Econ; 2021; 24(1):816-827. PubMed ID: 34126842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    Wu L; Zhong L
    J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a
    Cai B; Zhou ZY; Xue W; Hazra NC; Singh M; Mishra D; Brixner D; Oderda G; Biskupiak J
    J Med Econ; 2021; 24(1):131-139. PubMed ID: 33397178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension.
    Burudpakdee C; Shah A; Joish VN; Divers C; Yaldo A
    Am Health Drug Benefits; 2014 Dec; 7(9):479-87. PubMed ID: 25610527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
    Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
    J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
    Bajaj PS; Veenstra DL; Goertz HP; Carlson JJ
    J Med Econ; 2014 Aug; 17(8):538-46. PubMed ID: 24716717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health plan budget impact analysis for pimecrolimus.
    Chang J; Sung J
    J Manag Care Pharm; 2005; 11(1):66-73. PubMed ID: 15667234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated Budget Impact of Adopting the Affordable Care Act's Required Smoking Cessation Coverage on United States Healthcare Payers.
    Baker CL; Ferrufino CP; Bruno M; Kowal S
    Adv Ther; 2017 Jan; 34(1):156-170. PubMed ID: 27888437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy.
    Neeser K; O'Neil WM; Stern L; Harrow B; Travers K
    J Comp Eff Res; 2019 Jun; 8(8):577-587. PubMed ID: 30935213
    [No Abstract]   [Full Text] [Related]  

  • 20. Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA.
    Lin SW; Shapouri S; Parisé H; Bercaw E; Wu M; Kim E; Matasar M
    Pharmacoeconomics; 2024 May; 42(5):569-582. PubMed ID: 38300452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.